TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03731533

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WellStart
Description: 1. Five weekly automated text messages linked to an online article on health and wellness.~2. Five weekly automated health coach motivational text message to smart phone. Optional back and forth text with their health coach is available.~3. Daily Option to participate and post comments or questions in online discussion forum moderated by health coaches.~4. Three group (up to 20 participants) health coach online visits (60 minutes).~5. Two online group visits with a dietitian in groups of 10-12 participants.~6. Three one-on-one online visits with a Physician Advisor to review progress, review any changes in medications by the primary medical provider (PCP), review biometrics and lab results, review safety guidelines and symptoms (30 minutes).
Study: NCT03204318

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol/norethindrone acetate placebo
Description: E2 (0 mg)/NETA (0 mg) placebo capsule administered orally once daily and designed to match the E2/NETA capsule in size, shape, color, and odor.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Relugolix placebo
Description: Relugolix (0 mg) placebo tablet administered orally once daily and manufactured to match the relugolix tablet in size, shape, color, and odor.
Study: NCT00241722

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alvimopan

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04007263

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo via 30 minute infusion once daily for 5 days
Study: NCT03307993

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idalopirdine
Description: Idalopirdine 60-120 mg daily dose
Study: NCT03867396

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CROS
Description: Advanced Bionics CROS

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hearing Aid
Description: Advanced Bionics Naida hearing aid

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cochlear Implant Alone
Description: No hearing device on contralateral ear
Study: NCT02273648

Intervention type: DEVICE
Intervention: Drug Eluting Stent (DES)
Description: Percutaneous Coronary Intervention
Study: NCT01987427

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lorcaserin + phentermine placebo
Description: lorcaserin 10 mg BID + phentermine placebo BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lorcaserin + phentermine-HCl + phentermine placebo
Description: lorcaserin 10 mg BID + phentermine-HCl 15 mg QD + phentermine placebo QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lorcaserin + phentermine-HCl
Description: lorcaserin 10 mg BID + phentermine-HCl 15 mg BID
Study: NCT04007263

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NP10679
Description: NP10679 25 mg via 30 minute infusion once daily for 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NP10679
Description: NP10679 25 mg via 30 minute infusion once daily for 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NP10679
Description: NP10679 25 mg via 30 minute infusion once daily for 5 days
Study: NCT00363636

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Galiximab in combination with rituximab
Description: Galiximab (500mg/m2 IV) in combination with Rituximab (375 mg/m2 IV), weekly x 4

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab in combination with placebo
Description: Rituximab (375 mg/m2 IV) in combination with placebo, weekly x 4
Study: NCT03692559

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: full aseptic dressing
Description: Replacement of the central venous catheters in the dressing process
Study: NCT03418025

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT01187628

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fosrenol (Lanthanum Carbonate, BAY77-1931)
Description: Daily dose: 750-2250mg/day,(270-750mg each 3 times a day) for 52 weeks.
Study: NCT03418025

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Survey Administration
Description: Ancillary studies
Study: NCT00577083

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cap-fitted colonoscopy
Description: Subjects will be randomized to either initial cap-fitted colonoscopy or regular colonoscopy. Patients in the initial regular arm, will undergo cap-fitted colonoscopy for their second, tandem examination. Patients in the initial cap-fitted arm, will under undergo regular colonoscopy (without the cap) for their second, tandem examination.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cap-fitted colonoscopy
Description: Subjects will be randomized to either initial cap-fitted colonoscopy or regular colonoscopy. Patients in the initial regular arm, will undergo cap-fitted colonoscopy for their second, tandem examination. Patients in the initial cap-fitted arm, will under undergo regular colonoscopy (without the cap) for their second, tandem examination.
Study: NCT01469468

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: Day 1: Single dose of simvastatin 20 mg Day 8: single dose of simvastatin 20 mg (with PF-05175157)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05175157
Description: Days 2-9 inclusive: daily dosing of PF-05175157 200 mg
Study: NCT00907283

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferiprone
Description: 15 mg/Kg/twice for 1 year
Study: NCT04116710

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HS-110 (viagenpumatucel-L)
Description: Vaccine derived from irradiated human lung cancer cells genetically engineered to continually secrete gp96-Ig

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HS-130
Description: Vaccine derived from irradiated human lung cancer cells expressing the co-stimulatory fusion protein OX40L-Ig
Study: NCT03159884

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conbercept

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conbercept
Study: NCT00144586

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MRA(Tocilizumab)
Description: 8mg/kg/4 weeks
Study: NCT00473720

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Satraplatin
Description: Dose escalation of 40, 60 and 80 mg/m²/day on days 1-5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abraxane
Description: Dose escalation of 80 and 100 mg/mm²/day on days 1,8,15,22 every 28 days
Study: NCT01367769

Intervention type: OTHER
Intervention: No intervention
Description: There will be no intervention in this study.
Study: NCT00794196

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pharmaceutical care program for antidepressant treatment
Description: The pharmaceutical care program is a support program for patients starting and maintaining antidepressant treatment.
Study: NCT01411878

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reducing the Risk
Description: Reducing the Risk: Building Skills to Prevent Pregnancy, STD and HIV (RtR) was developed by Richard Barth, MSW, Ph.D. in California. The training manual is in its 5th Edition and was last published in 2011. This curriculum is one of the first that was evaluated using an experimental design, with a longitudinal follow up (6 months and 18 months) and tested on a large group of high school students (N = 758). It is also one of the first programs to show an impact on beliefs of adolescent sexual behavior prevalence and actual behavior as well as increasing parent-child communication about abstinence and contraception (Kirby, Barth, Leland, and Fetro, 1991).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Love Notes
Description: The second healthy relationships program for high-risk youth, Love Notes, was developed to educate participants about healthy relationships, including issues of decision-making, communication and conflict resolution, and overall safety, including the prevention of pregnancy and sexually transmitted disease (Pearson, 2009). Love Notes is a derivative of the Prevention and Relationship Enhancement Program (PREP; Stanley, Markman, \& Jenkins, 2009), which is relationship marriage education program listed as an evidence-based practice (EBP) by SAMSHA (www.samhsa.gov). This curriculum builds on social exchange theory and meets the needs of youth who are alienated and in need of loving personal relationships.
Study: NCT03706807

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Intervention
Description: This intervention is a meditative practice which the individuals will practive in their daily life following the MBHP protocol

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Stimulation
Description: A basic computer workshop in order to develop the psychomotricity involving the use of mouse, keyboard, MS paint, photo gallery and PowerPoint presentations to surf on the internet, learn how to play online games and use social networks
Study: NCT02376166

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: 850 mg PO twice daily for the remainder of the study period (the dose of metformin will be increased to the 850 mg PO twice daily dose in the absence of grade \> 1 toxicities)
Study: NCT02694419

Intervention type: DEVICE
Intervention: Doppler evaluation
Description: Endometrial volume, endometrial and subendometrial vascularity indices are measured by 3D power Doppler

Intervention type: DEVICE
Intervention: Doppler evaluation
Description: Endometrial volume, endometrial and subendometrial vascularity indices are measured by 3D power Doppler

Intervention type: DEVICE
Intervention: Doppler evaluation
Description: Endometrial volume, endometrial and subendometrial vascularity indices are measured by 3D power Doppler

Intervention type: DEVICE
Intervention: Doppler evaluation
Description: Endometrial volume, endometrial and subendometrial vascularity indices are measured by 3D power Doppler
Study: NCT02254538

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BILR 355 BS

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG 400

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PEG 400
Study: NCT03616314

Intervention type: DEVICE
Intervention: stepping verticalization plus functional electrical stimulation
Description: patients hospitalized in ICU are rehabilitated using 30 minutes/day of conventional physiotherapy + 30 minutes/day of verticalization using a tilt table with an integrated robotic stepping device synchronized with an electrical stimulation of the lower limbs muscles

Intervention type: DEVICE
Intervention: stepping verticalization
Description: patients receive 30 minutes/day of conventional physiotherapy + 30 minutes7day of verticalization using a tilt table with a robotic stepping device
Study: NCT03678649

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 1000-1250 mg/m2 orally twice daily for 14 days followed by a 1-week rest period, given as 3- week cycles for a total of 6 cycles .
Study: NCT02941679

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCP1202
Description: Hanmi Pharmaceutical. Co., Ltd.
Study: NCT03616314

Intervention type: OTHER
Intervention: conventional physiotherapy
Description: patients are treated only with 60 minutes/day of conventional physiotherapy
Study: NCT02769390

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clonidine 1 mcg/Kg
Description: Clonidine 1 mcg/Kg associated with bupivacaine 0,166% 1 ml/Kg administred epidural caudal in children for hypospadias surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clonidine 2 mcg/ Kg
Description: Clonidine 2 mcg//Kg associated with bupivacaine 0,166% 1 ml/Kg administred epidural caudal in children for hypospadias surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clonidine 3 mcg/ Kg
Description: Clonidine 3 mcg //Kg associated with bupivacaine 0,166% 1 ml/Kg administred epidural caudal in children for hypospadias surgery
Study: NCT04148508

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tailored Emotional Competence Self-help
Description: The active interventions are all entirely self-help and provide psycho-education, tips, advice and strategies for well-being promotion. Interventions are personalised to the individual based on emotional competence skills. Intervention is in addition to self-monitoring in the app. Intervention components include selection of 2 from 4 of : targeting worry and rumination; increasing emotional knowledge and perception skills; improving achievement appraisals including attribution retraining and growth mindset; improving social appraisals including positive interpretations of ambiguous social events

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive-behavioural Approach
Description: The active interventions are all entirely self-help and provide psycho-education, tips, advice and strategies for well-being promotion, based on cognitive-behavioural principles such as increased activity and challenging negative thinking. Interventions are generic and common to all participants. Intervention is in addition to self-monitoring in the app.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-monitoring
Description: Self-monitoring app that involves monitoring emotions and emotional events over time within the app and being able to review emotion over time

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Self-monitoring
Description: Self-monitoring app that involves monitoring emotions and emotional events over time within the app and being able to review emotion over time

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-monitoring
Description: Self-monitoring app that involves monitoring emotions and emotional events over time within the app and being able to review emotion over time
Study: NCT04401995

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vidutolimod (CMP-001)
Description: A molecule comprised of a 30 nucleotide strand, flanked by 10 guanines on either end. The nucleotide strand is surrounded by a Qβ viral-like protein. The intended mechanism of action of CMP-001 in oncology is the activation of TLR9 in pDC within the tumor or the tumor-draining lymph nodes (tumor-associated pDC).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: a fully human Ig G4 antibody that blocks PD-1. Nivolumab was initially approved by the FDA for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor. Nivolumab has also been FDA approved to treat patients with advanced squamous non-small cell lung cancer (NSCLC) with progression on or after platinum-based chemotherapy, as well as advanced renal cell carcinoma.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: a fully human Ig G4 antibody that blocks PD-1. Nivolumab was initially approved by the FDA for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor. Nivolumab has also been FDA approved to treat patients with advanced squamous non-small cell lung cancer (NSCLC) with progression on or after platinum-based chemotherapy, as well as advanced renal cell carcinoma.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: [18F]F-AraG PET/CT
Description: \[18F\]F-AraG is an 18F-labeled analog of arabinofuranosylguanine (AraG), a compound that has shown remarkably selective accumulation in T cells. It has several advantages over conventional \[18F\] and existing small molecule PET agents being investigated for immuno-monitoring. \[18F\]F-AraG has lower accumulation and more efficient efflux from cancer cells than a dCK agent.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: [18F]F-AraG PET/CT
Description: \[18F\]F-AraG is an 18F-labeled analog of arabinofuranosylguanine (AraG), a compound that has shown remarkably selective accumulation in T cells. It has several advantages over conventional \[18F\] and existing small molecule PET agents being investigated for immuno-monitoring. \[18F\]F-AraG has lower accumulation and more efficient efflux from cancer cells than a dCK agent.
Study: NCT00285259

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VCL-CB01
Description: 5 mg/mL, Intramuscular (IM.) 3 vaccinations for donors; 1 vaccination pretransplant, up to 3 vaccinations after transplant for recipients
Study: NCT00279916

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone acetonide nasal spray
Description: Subjects aged 12 years or older received 2 metered sprays in each nostril once daily (55 micrograms/spray) (total daily dose 220 micrograms).~Subjects younger than 12 years old received received 1 metered spray in each nostril once daily (55 micrograms/spray) (total daily dose 110 micrograms).
Study: NCT00285259

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Phosphate-buffered Saline (PBS)
Description: 1 mL, IM. 3 vaccinations for donors; 1 vaccination pretransplant, up to 3 vaccinations after transplant for recipients
Study: NCT04177472

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Obesity Prevention Group
Description: Parents will be provided with responsive feeding coaching to help them recognize hunger and satiety cues and nutrition coaching that involves recommending a sequence of introducing complementary foods that corresponds with food textures and feeding styles, breast/bottle weaning, healthy snacking and hands on demonstrations for healthy food options.
Study: NCT02941679

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HGP1011
Description: Boehringer Ingelheim

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HCP0910
Description: GlaxoSmithKline
Study: NCT03857633

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiac MRI 1 - With Gadolinium Contrast
Description: Cines for cardiac function and volumes, T2 myomaps, Resting perfusion and strain analysis, Tagging (strain), T1 myomaps, Late gadolinium enhancement~During the MRI scan participants would be required perform a short period of low intensity exercise involving peddling on an adapted cycle for 10-15 minutes to provide additional data on cardiac function under exertion.

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiac MRI 2 - With Gadolinium Contrast
Description: Cines for cardiac function and volumes, T2 myomaps, Resting perfusion and strain analysis, Tagging (strain), T1 myomaps, Late gadolinium enhancement~During the MRI scan participants would be required perform a short period of low intensity exercise involving peddling on an adapted cycle for 10-15 minutes to provide additional data on cardiac function under exertion.

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiac MRI 3 - Without Gadolinium Contrast
Description: Cines for cardiac function and volumes, T2 myomaps, Resting perfusion and strain analysis, Tagging (strain), T1 myomaps.~During the MRI scan participants would be required perform a short period of low intensity exercise involving peddling on an adapted cycle for 10-15 minutes to provide additional data on cardiac function under exertion.
Study: NCT04177472

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Obesity Prevention Group + Food Boxes
Description: Parents will be provided with responsive feeding coaching to help them recognize hunger and satiety cues and nutrition coaching that involves recommending a sequence of introducing complementary foods that corresponds with food textures and feeding styles, breast/bottle weaning, healthy snacking and hands on demonstrations for healthy food options. Parents will also be provided with grocery items (fruits, vegetables, meat) prior to each intervention visit to facilitate a healthy family diet.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Infant Safety and Injury Prevention Group
Description: Parents will be provided with information about safe sleeping, car seats, baby-proofing, etc., delivered during home visits, newsletters, and reinforcing text messages.
Study: NCT04482894

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Palliative Care Visits
Description: Regular visits with a palliative (supportive) care specialist
Study: NCT02495974

Intervention type: DRUG
Intervention: enzalutamide
Description: oral
Study: NCT03857633

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiac MRI 3 - With Gadolinium Contrast
Description: Cines for cardiac function and volumes, T2 myomaps, Resting perfusion and strain analysis, Tagging (strain), T1 myomaps, Late gadolinium enhancement~During the MRI scan participants would be required perform a short period of low intensity exercise involving peddling on an adapted cycle for 10-15 minutes to provide additional data on cardiac function under exertion.

Intervention type: DIAGNOSTIC_TEST
Intervention: Peripheral Whole Blood Samples
Description: 20ml EDTA whole blood samples - collected sequentially during study - max 8 time points